Skip to main content

$0.091 0.002 (2.25%)

High

$0.10

Low

$0.09

Trades

2,797

Turnover

$4,713,392

Volume

50,159,971
30 June 2023 at 4:59pm
Register to track IMU and receive email alerts.
Subject
IMU Ann: Imugene Presents New PD1-Vaxx Data at the 2022 WCLC

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Imugene appoints experienced life sciences CFO Mike Tonroe

IMU Ann: IMU to Present New PD1-Vaxx Data at the WCLC 2022

IMU Ann: Appointment of Dr Sharon Yavrom as Clinical Scientist

IMU Ann: Investor Webinar - Final HER-Vaxx Overall Survival Results

IMU Ann: Final HER-Vaxx Phase 2 Trial Overall Survival Results

IMU Ann: Change of Director's Interest Notice - CW

IMU Ann: Change of Director's Interest Notice - LR

IMU Ann: Notice Under Section 708A

IMU Ann: Application for quotation of securities - IMU

IMU Ann: IMUGENE APPOINTS DR YANGHEE WOO TO SCIENTIFIC ADVISORY BOARD

IMU Ann: IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022

IMU Ann: IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT

IMU Ann: Letter to Shareholders

IMU Ann: IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL

IMU Ann: IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON

IMU Ann: Response to ASX Query

IMU Ann: Clarification Announcement

IMU Ann: Pause in Trading

IMU Ann: Termination of Supply Agreement

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMU Ann: First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

IMU Ann: Release of Securities from Escrow

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Dose Escalation in Phase 1 Clinical Trial of CHECKvacc

IMU Ann: Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia

IMU Ann: Investor webinar Imugene & Merck collaboration

IMU Ann: Imugene HER-Vaxx Clinical Trial Collaboration with Merck

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Half Yearly Report and Accounts

IMU Ann: Science Series CHECKvacc

IMU Ann: Notice Under Section 708A

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Change of Director's Interest Notice - JE

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Notice Under Section 708A

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Application for quotation of securities - IMU

IMU Ann: BPAY or EFT Process for IMUOC & IMUOD Option Holders

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Appointment of Dr Steven Cha as Chief Medical Officer

IMU Ann: Issue of Options under the Employee Share Option Plan

IMU Ann: Oncolytic Virotherapy CF33 Patent Granted in Japan

IMU Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMU Ann: PD1-Vaxx Clinical Trial Supply Agreement with Roche

Register to track IMU and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
MSB
OPT
PAR
PYC
RAC
TLX